Cell line · CVCL_0131
Papers107
1 to 20 of 107
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Genetically engineered RNA inducers of proximity for protein regulation. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeted degradation of P-TEFb via MDM2 substrate substitution collapses oncogenic transcriptional programs in MDM2-amplified cancers. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A guide to selecting high-performing antibodies for TMEM175 (UniProt ID: Q9BSA9) for use in western blot, immunoprecipitation, and immunofluorescence. | F1000Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CUDC-907 inhibits glioblastoma and enhances glioblastoma sensitivity to temozolomide by inhibiting DNA damage repair. | Genes Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. | Mol Biomed | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CREsted: modeling genomic and synthetic cell-type-specific enhancers across tissues and species. | Nat Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Spirohydantoin derivatives exert dopamine D2-like receptor-independent cytotoxicity in glioblastoma cells with possible involvement of calpain inhibition. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Ferroptosis resistance-related TEP1 as a novel prognostic biomarker involved in immune cell infiltration and tumour progression in glioblastoma. | Cancer Cell Int | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial connexin 43 modulates metabolic stress adaptation in glioma cell lines. | Cell Commun Signal | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Quercetin Increases Expression of Membrane-TRAIL in Glioblastoma Cells Resulting in Apoptosis. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Downregulation of miR-27a-3p Modulates TGF-β Signaling and Dysregulates Metabolism in Glioblastoma. | Int J Mol Sci | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cell Settling, Migration, and Stochastic Cancer Gene Expression Suggest Potassium Membrane Flux May Initiate pH Reversal. | Biomolecules | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Therapy-induced senescence of glioblastoma cells is determined by the p21CIP1-CDK1/2 axis and does not require activation of DREAM. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The alternatively spliced diacylglycerol kinase gamma-Δ exon13 transcript generated under hypoxia promotes glioblastoma progression. | Oncol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| RNA Sequencing Identifies Novel Signaling Pathways and Potential Drug Target Genes Induced by FOSL1 in Glioma Progression and Stemness. | Biologics | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional loss of ERBB receptor feedback inhibitor 1 (MIG6) promotes glioblastoma tumorigenesis by aberrant activation of epidermal growth factor receptor (EGFR). | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional screening reveals genetic dependencies and diverging cell cycle control in atypical teratoid rhabdoid tumors. | Genome Biol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma. | Int J Mol Sci | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0131/papers